Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

CP-610431

CP-610431
Contact us for more batch information

CP-610431

Catalog No. T40675Cas No. 591778-83-5
CP-610431 is a reversible, ATP-uncompetitive inhibitor of acetyl-CoA carboxylase (ACC), exhibiting isozyme nonselectivity. It inhibits both ACC1 and ACC2 with IC50 values of approximately 50 nM. CP-610431 offers potential application in metabolic syndrome research.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
5 mg$970Backorder
Bulk & Custom
Add to Cart
Questions
View More

Product Introduction

Bioactivity
Description
CP-610431 is a reversible, ATP-uncompetitive inhibitor of acetyl-CoA carboxylase (ACC), exhibiting isozyme nonselectivity. It inhibits both ACC1 and ACC2 with IC50 values of approximately 50 nM. CP-610431 offers potential application in metabolic syndrome research.
In vitro
CP-610431, the active R-enantiomer of CP-497485, demonstrates greater potency than its racemate, CP-497485, and significantly surpasses the S-enantiomer, CP-610432, in inhibiting rat ACC1 (IC 50=35.7 nM) and ACC2 (IC 50=55 nM), with the latter showing negligible inhibition up to 3 μM. It notably inhibits fatty acid and triglyceride synthesis, along with TG and apolipoprotein B secretion in HepG2 cells, achieving EC 50 values of 1.6, 1.8, 3.0, and 5.7 μM, respectively, without impacting cholesterol synthesis or apolipoprotein CIII secretion. Consistently, CP-610431 inhibits ACC activity in the liver and skeletal muscle of rats, mice, and cynomolgus macaques with comparable effectiveness. Furthermore, it efficiently inhibits fatty acid and TG synthesis in mouse primary hepatocytes, with IC 50 values of 0.11 and 1.2 μM respectively, and TG secretion with an IC 50 of 10 μM. A Cell Viability Assay on HepG2 cells, treated with concentrations of 0.1, 1, and 10 μM for 24 hours, revealed dose-dependent inhibition of fatty acid and TG synthesis, as well as TG and apoB secretion, confirming its impactful biochemical activities.
In vivo
CP-610431 effectively inhibits fatty acid synthesis in both CD1 and ob/ob mice within one hour of administration, demonstrating ED50 values of 22 and 4 mg/kg, respectively[1]. In CD1 mice, doses of 30 and 100 mg/kg reduced hepatic fatty acid synthesis by 64±12% and 77±4% in fasting conditions, while in non-fasting conditions, doses of 10, 30, and 100 mg/kg achieved inhibition rates of 18%, 51%, and 75%, respectively. These results were achieved through intraperitoneal administration, highlighting CP-610431's potent effect on fatty acid synthesis suppression across different physiological states.
Chemical Properties
Molecular Weight471.645
FormulaC30H37N3O2
Cas No.591778-83-5
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords